Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419757 · ClinicalTrials.gov registry record · Phase 3
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
- 20
- Study locations
NCT00419757 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 558 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00419757, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
Conditions Studied
Interventions
- DRUG Budesonide/formoterol (SYMBICORT) pMDI
- DRUG Budesonide HFA pMDI
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Chula Vista
- Research Site - Fresno
- Research Site - Fullerton
- Research Site - Los Angeles
- Research Site - National City
- Research Site - Rancho Cordova
- Research Site - Rancho Mirage
- Research Site - Riverside
- Research Site - Sacramento
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - Stockton
- Research Site - Torrance
Florida
- Research Site - Largo
- Research Site - Miami
- Research Site - Naranja
- Research Site - North Miami
- Research Site - Orlando
Colorado
- Research Site - Pueblo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419757
The ClinicalTrials.gov registry entry for NCT00419757 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Budesonide/formoterol (SYMBICORT) pMDI is the first listed.
NCT00419757 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00419757 about?
NCT00419757 is a clinical study titled "An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma". The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
What is the current status of trial NCT00419757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2007-01. Estimated completion is 2008-06.
What conditions does trial NCT00419757 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00419757?
The interventions under investigation include: Budesonide/formoterol (SYMBICORT) pMDI (DRUG), Budesonide HFA pMDI (DRUG).
Who is sponsoring clinical trial NCT00419757?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00419757 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.